Genmab A (GMAB) Payables (2023 - 2026)

Genmab A (GMAB) has reported Payables for 4 consecutive years, with $294.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables changed N/A year-over-year to $294.0 million; the trailing twelve-month figure through Jun 2026 stood at $294.0 million (changed N/A YoY), and the FY2025 full-year result was $418.0 million, up 597.61% from the prior year.
• Payables declined to $294.0 million in Q2 2026 per GMAB's latest filing, from $418.0 million in the prior quarter.
• Across five years, Payables topped out at $418.0 million in Q4 2025 and bottomed at $31.0 million in Q4 2023.
• Historically, Payables has averaged $200.7 million across 4 years, with a median of $177.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Payables surged 93.28% in 2024, then surged 597.61% in 2025.
• Over 4 years, Payables stood at $31.0 million in 2023, then soared by 93.28% to $59.9 million in 2024, then soared by 597.61% to $418.0 million in 2025, then retreated by 29.67% to $294.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $294.0 million, $418.0 million, and $59.9 million for Q2 2026, Q4 2025, and Q4 2024 respectively.